{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:57:04Z","timestamp":1790672224362,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"DOI":"10.1038\/s41409-026-03057-y","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:59:24Z","timestamp":1790668764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy"],"prefix":"10.1038","author":[{"given":"Sergi","family":"Camarillas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3195-5470","authenticated-orcid":false,"given":"Anna","family":"Alonso-Saladrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-4605","authenticated-orcid":false,"given":"V\u00edctor","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Marsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gueda","family":"Molinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9377-423X","authenticated-orcid":false,"given":"Javier","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-5860","authenticated-orcid":false,"given":"Alex","family":"Rampotas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Roddie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-7280","authenticated-orcid":false,"given":"Veit","family":"B\u00fccklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2301-1367","authenticated-orcid":false,"given":"Mario","family":"S\u00e1nchez-Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7174-5451","authenticated-orcid":false,"given":"Berta","family":"Gonz\u00e1lez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana \u00c1frica","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3727-5716","authenticated-orcid":false,"given":"Anna","family":"Torrent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6436-9195","authenticated-orcid":false,"given":"Antonio","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-9288","authenticated-orcid":false,"given":"Gloria","family":"Iacoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-1831","authenticated-orcid":false,"given":"Susana","family":"Rives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7076-7969","authenticated-orcid":false,"given":"Pere","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"3057_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"3057_CR2","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414\u201324.","journal-title":"Blood Adv"},{"key":"3057_CR3","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41:1664\u20139.","journal-title":"J Clin Oncol"},{"key":"3057_CR4","doi-asserted-by":"publisher","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024;391:2219\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2406526.","DOI":"10.1056\/NEJMoa2406526"},{"key":"3057_CR5","doi-asserted-by":"publisher","first-page":"1151744","DOI":"10.3389\/frhem.2023.1151744","volume":"2","author":"CL Phillips","year":"2023","unstructured":"Phillips CL, Krupski C, Khoury R, Dandoy CE, Nelson AS, Galletta TJ, et al. Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. Front Hematol. 2023;2:1151744.","journal-title":"Front Hematol"},{"key":"3057_CR6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood.2022016937","volume":"141","author":"RM Myers","year":"2023","unstructured":"Myers RM, Shah NN, Pulsipher MA. How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL. Blood. 2023;141:1251\u201364.","journal-title":"Blood"},{"key":"3057_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502.","journal-title":"Lancet"},{"key":"3057_CR8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/bloodadvances.2023011168","volume":"8","author":"M Gabelli","year":"2024","unstructured":"Gabelli M, Oporto-Espuelas M, Burridge S, Chu J, Farish S, Hedges E, et al. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy. Blood Adv. 2024;8:1959\u201363.","journal-title":"Blood Adv"},{"key":"3057_CR9","doi-asserted-by":"publisher","unstructured":"Jiang H, Li C, Yin P, Guo T, Liu L, Xia X, et al. Anti-CD19 chimeric antigen receptor-modified T cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial. Am J Hematol. 2019;94:1113\u201322. https:\/\/doi.org\/10.1002\/ajh.25582.","DOI":"10.1002\/ajh.25582"},{"key":"3057_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1709919.","journal-title":"N Engl J Med"},{"key":"3057_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33:259\u201375.","journal-title":"Ann Oncol"},{"key":"3057_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142:865\u201377.","journal-title":"Blood"},{"key":"3057_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.651944","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu X, Chen S, Zhao Z, Xiao X, Huang S, Huo Z, et al. Consolidative hematopoietic stem cell transplantation after CD19 CAR-T cell therapy for acute lymphoblastic leukemia: a systematic review and meta-analysis. Front Oncol. 2021;11:651944.","journal-title":"Front Oncol"},{"key":"3057_CR14","doi-asserted-by":"crossref","unstructured":"Ribera JM, Torrent A, Morgades M, Barrena S, Ribera J, Genesc\u00e0 E, et al. Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood 2026;148:939\u201356.","DOI":"10.1182\/blood.2025032645"},{"key":"3057_CR15","first-page":"21","volume":"28","author":"C Summers","year":"2022","unstructured":"Summers C, Wu QV, Annesley C, Bleakley M, Dahlberg A, Narayanaswamy P, et al. Hematopoietic cell transplantation after CD19 chimeric antigen receptor T-cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage. Transpl Cell Ther. 2022;28:21\u20139.","journal-title":"Transpl Cell Ther"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03057-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03057-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03057-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:59:26Z","timestamp":1790668766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03057-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":15,"alternative-id":["3057"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03057-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Roddie. Honoraria: Gilead; Consulting: Autolus, Kite\/Gilead; BMS\/Celgene; Speakers\u2019 bureau: Novartis, Gilead; Travel, accommodations: Gilead, Autolus. Subklewe. Consulting: Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer; Speakers bureau: Amgen, Celgene, Gilead, Pfizer, Octapharm, Novartis; Research funding: Amgen, Gilead, Miltenyi, Seagen, Novartis, Celgene; Travel, accommodations: Celgene, Gilead, Amgen. S\u00e1nchez-Salinas. Honoraria: Celgene\/BMS. Martin. Travel, accommodations: Kite\/Gilead. Torrent. Honoraria: Incyte, Kite, Amgen. Iacoboni. Honoraria: AbbVie, AstraZeneca, BMS, Kite\/Gilead, Miltenyi, Novartis, Lilly; Consulting: Novartis, Autolus, BMS, Kite\/Gilead, Miltenyi; Travel, accommodations: AbbVie, AstraZeneca, Kite\/Gilead, Miltenyi. Rives. Honoraria: Novartis, Servier, Celgene\/BMS, Kite\/Gilead, Pfizer, Clinigen, Amgen. Barba: Consulting: Adicet, Allogene, BMS, Kite\/Gilead, Nektar, Novartis, Pierre Fabre, Miltenyi, Pfizer. Travel, accommodations: Kite\/Gilead, Pfizer, Novartis, Pierre Fabre. The rest of the authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All patients provided informed consented and the study was approved by the Ethics Committee of Vall d\u2019Hebron University Hospital (PR(AG)150\/2025).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}